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Multiple binding afﬁnitiesTo date, 11C-(R)-PK11195 has been the most widely used TSPO PET imaging probe, although it suffers from
high non-speciﬁc binding and low signal to noise. A signiﬁcant number of 2nd generation TSPO radioligands
have been developed with higher afﬁnity and/or lower non-speciﬁc binding, however there is substantial
inter-subject variation in their afﬁnity for the TSPO. TSPO from human tissue samples binds 2nd generation
TSPO radioligands with either high afﬁnity (high afﬁnity binders, HABs), or low afﬁnity (LABs) or expresses
both HAB and LAB binding sites (mixed afﬁnity binders, MABs). The expression of these different TSPO bind-
ing sites in human is encoded by the rs6971 polymorphism in the TSPO gene. Here, we use a predictive
biomathematical model to estimate the in vivo performances of three of these 2nd generation radioligands
(18F-PBR111, 11C-PBR28, 11C-DPA713) and 11C-(R)-PK11195 in humans. The biomathematical model only
relies on in silico, in vitro and genetic data (polymorphism frequencies in different ethnic groups) to predict
the radioactivity time course in vivo. In particular, we provide estimates of the performances of these ligands
in within-subject (e.g. longitudinal studies) and between-subject (e.g. disease characterisation) PET studies,
with and without knowledge of the TSPO binding class. This enables an assessment of the different radioli-
gands prior to radiolabelling or acquisition of any in vivo data.
The within-subject performance was characterised in terms of the reproducibility of the in vivo binding
potential (%COV[BPND]) for each separate TSPO binding class in normal and diseased states (50% to 400% in-
crease in TSPO density), whilst the between-subject performance was characterised in terms of the number
of subjects required to distinguish between different populations.
The results indicated that the within-subject variability for 18F-PBR111, 11C-PBR28 and 11C-DPA713 (0.9% to
2.2%) was signiﬁcantly lower than 11C-(R)-PK11195 (16% to 36%) for HABs and MABs in both normal and dis-
eased states. For between-subject studies, sample sizes required to detect 50% differences in TSPO density
with the 2nd generation tracers are approximately half that required with 11C-(R)-PK11195 when binding
class information is known a priori. As binding class can be identiﬁed using a simple genetic test or from pe-
ripheral blood assays, the combination of binding class information with 2nd generation TSPO imaging data
should provide superior tools to investigate inﬂammatory processes in humans in vivo.
© 2012 Elsevier Inc.Open access under CC BY license.Introduction
Neuroinﬂammation plays an important role in neurodegenerative
disorders, and thus there is a demand for reliable imaging markers of
inﬂammatory processes that can act as diagnostic tools and support
the development of new drugs. Positron Emission Tomography
(PET) has the unique ability to provide quantitative information of ac-
tive inﬂammatory processes by targeting the translocator protein
(TSPO, formerly known as the peripheral benzodiazepine receptor).uilding, Division of Experimental
al, Du Cane Road, London W12
 license.The TSPO has been observed in higher density in activated macro-
phages and microglia across various brain diseases (Banati, 2002).
TSPO expression has been imaged in the central nervous system
(CNS) using the selective antagonist PK11195 labelled with the posi-
tron emitting radionuclide C-11 for more than 15 years (Cagnin et al.,
2007; Shah et al., 1994). Imaging of neuroinﬂammatory processes has
been demonstrated with 11C-(R)-PK11195 in traumatic, inﬂammato-
ry, degenerative, and neoplastic diseases (Cagnin et al., 2007). How-
ever, the high non-speciﬁc binding of 11C-(R)-PK11195, its low
extraction in brain and the resulting poor signal-to-noise ratio
of 11C-(R)-PK11195 have led to the need for improved TSPO
PET radioligands. In the past 5 years, more than 50 candidate 2nd
generation TSPO ligands have been introduced, with some offering
higher speciﬁc to non-speciﬁc signals including 18F-FEPPA, 18F-
903Q. Guo et al. / NeuroImage 60 (2012) 902–910PBR111, 11C-PBR28, 11C-DPA713, 11C-DAA1106, and 11C-AC-5126
(Chauveau et al., 2008).
However, the use of these 2nd generation TSPO radioligands has
been complicated by the existence of apparent “non-binders” that
were identiﬁed in approximately 10% of humans scanned with the
prototypical radioligand, 11C-PBR28 (Brown et al., 2007; Fujita et al.,
2008; Kreisl et al., 2010). These subjects appeared not to bind
PBR28. In vitro radioligand binding studies using post-mortem
human brain tissue revealed substantial population variation in the
afﬁnity of PBR28 for the TSPO. “Low afﬁnity binders” (LABs) have a
marked reduction in afﬁnity for PBR28 (Ki~188 nM) in comparison
to “high afﬁnity binders” (HABs, Ki~3.4 nM). Hence LABs do not pro-
duce a measurable speciﬁc signal in PET studies with 11C-PBR28 and
appear as “non-binders” (Owen et al., 2010). A third group was also
identiﬁed (“mixed afﬁnity binders” (MABs)), who express the HAB
and LAB binding sites in approximately equal number (Owen et al.,
2010). This variation in binding afﬁnity is not speciﬁc to PBR28; all
TSPO radioligands tested behave in a similar manner, but for
PK11195 which appears to bind with similar afﬁnity in all subjects
(Owen et al., 2011). This variation in binding afﬁnity is due to a single
nucleotide polymorphism (rs6971) in the gene encoding the TSPO
(Owen et al., 2012), which causes a substitution of threonine and al-
anine at position 147 (Ala147Thr). This substitution is common in
Caucasians: 49% of subjects are Ala-Ala (HABs), 42% are Ala-Thr
(MABs), and 9% are Thr-Thr (LABs), but its prevalence varies across
ethnic groups.
The existence of HABs, MABs and LABs complicates the inter-
pretation of the speciﬁc binding signal, as the binding signal of a par-
ticular TSPO ligand depends on its ratio of afﬁnities for the high- and
low-afﬁnity sites, and the binding class of the individual. Therefore
measured differences in vivo could simply result from a difference
in afﬁnity (binding class) rather than TSPO density. Since the binding
class is consistent within each subject for all the 2nd generation
ligands tested to date, genotyping the rs6971 polymorphism can
help the quantitative assessment of TSPO ligand binding, by allowing
binding afﬁnity to be predicted at screening.
The aim of this work is to use predictive biomathematical models
to investigate the performance and utility of some of the most prom-
ising 2nd generation TSPO radioligands, namely 18F-PBR111, 11C-
PBR28, and 11C-DPA713, in both within-subject and between-
subject studies, taking into account multiple binding classes, and
compare their quantitative performance with 11C-(R)-PK11195.
These predictive biomathematical models allow for a prediction of
the in vivo performance simply by using appropriate in silico and in
vitro data and have been validated previously for a wide range of
ligands that do not involve genetic variability (Guo et al., 2009). In
this work, we extend the previous approach to account for a genetic
dependency of the signal which is a consequence of the multiple
TSPO binding classes and afﬁnities whose frequencies can also differ
across ethnic groups. This approach facilitates the identiﬁcation of op-
timal TSPO PET tracers prior to the acquisition of any in vivo data.
For example, we evaluate in longitudinal studies whether these radi-
oligands are likely to be more sensitive to detect ﬂuctuations in
inﬂammation processes (fewer number of subjects required for
equivalent power) than 11C-(R)-PK11195 for each of the binding
classes, and whether these 2nd generation radioligands are superior
to 11C-(R)-PK11195 in between-subject studies designed to compare
healthy subjects to those with a particular disease, with and without
knowledge of their binding classes.
Materials and methods
The outline of the biomathematical framework
The outline of the biomathematical framework is shown in Fig. 1
and is based on approximating the tracer's behaviour by a singletissue compartment model (1TCM). In silico, in vitro data, and phys-
iological parameters were used to predict the inﬂux (K1), efﬂux rate
constants (k2) as well as the binding potential (BPND, deﬁned as the
ratio of speciﬁcally bound to nondisplaceable radioligand in tissue,
(Innis et al., 2007)) for the compartmental structure. In order to ac-
count for the multiple afﬁnities, binding class status was used to de-
termine the appropriate speciﬁc signal for different individuals.
Monte Carlo simulations were used to generate a large population
of BPND values for groups in healthy and diseased states with different
TSPO levels. For within-subject studies, the numerical identiﬁability
of the ligands BPND were evaluated and sample sizes required for
follow up studies were estimated. For between-subject studies, with
additional information on the frequency of different binding classes
in an ethnic group (Owen et al., 2012), we investigated the power
of the different radioligands to distinguish diseased from healthy sub-
jects in terms of the minimal sample sizes required with and without
knowledge of the binding class status of each subject.
The in silico/in vitro data
The in silico and in vitro data required by the biomathematical
models to predict the in vivo radioligand performance include the
lipophilicity (clogD), McGowan molecular volume (Vx), free fractions
in plasma and tissue (fp and fND), target density (Bmax) and afﬁnity
represented by KD or Ki (Guo et al., 2009).
Here, the clogD and Vx of 18F-PBR111, 11C-PBR28, 11C-DPA713 and
11C-(R)-PK11195 were determined using in-house in silico models
based on the structures of the compounds. The fP and fND were mea-
sured from Landrace pig tissue (blood and brain — obtained from
Charles River Laboratories, Tranent, Scotland) using equilibrium dial-
ysis (Summerﬁeld et al., 2006). In brief, the cold test compounds were
spiked into plasma or brain homogenate at a concentration of 1 μg/g
and dialysed against phosphate buffered saline (PBS, pH 7.4) for 5 h
at 37 °C. Aliquots (20–50 μL) of plasma, brain and dialysate were
taken and extracted using acetonitrile containing internal standard,
followed by LC–MS/MS analysis. The free fractions were determined
as the concentration ratio of analyte in dialysate to that in plasma
or brain. The density of TSPO in different binding classes and afﬁnities
of these compounds was obtained from literature (Owen et al., 2010,
2011). The Bmax was measured in post mortem brain samples in cor-
tex (with no evidence of inﬂammation on immunohistochemistry)
obtained from UK MS tissue bank using homogenate saturation bind-
ing assays at 37 °C with 3H-PK11195 (purchased from Perkin Elmer,
Cambridge, UK) and 3H-PBR28 (custom labelled by GE Healthcare,
Amersham, UK) respectively (Owen et al., 2010). Afﬁnity (Ki) of
PBR111, DPA713, PBR28, and PK11195 was measured using competi-
tion assays for each binding class with 3H-PK11195 at 37 °C (Owen
et al., 2011).
The biomathematical modelling approach
A biomathematical modelling approach was used to predict the in
vivo performance of the radioligands whilst accounting for multiple
binding classes (Fig. 1). The use of the approach to predict how
good a radioligand is for a single target has been described in detail
previously (Guo et al., 2009). In brief, it uses a 1TCM to approximate
both the non-displaceable and total uptake of a radioligand. The
1TCM is described by a parsimonious parameter set including the in-
ﬂux rate constant K1, the efﬂux rate constant of the non-displaceable
tissue k2, and the binding potential BPND, all of which can be predicted
from the in silico and in vitro data. The approach assumes that the
radioligands cross the blood brain barrier (BBB) by passive diffusion
and yields equations for K1 and k2 as:
K1 ¼ f 1−e−
PS
f
 
ð1Þ
Fig. 1. The framework of the biomathematical modelling approach to evaluate the performances of the TSPO ligands.
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P ¼ 10−0:121 c logD−2:298ð Þ
2−2:544 log Vx 1=3ð Þ−2:525 ð2Þ
k2 ¼
Vaq p K1
Vaq T
f ND
f p
ð3Þ
where f is perfusion in units ofmL·cm−3·min−1, P is the permeability of
the compound in cm·min−1, S is the capillary surface area in cm2·cm−3,
Vaq_P and Vaq_T are the apparent aqueous volume to correct for the small
volume that cannot be reached by solvent in plasma and tissue respec-
tively. In this paper, the following values were used for these physiolog-
ical parameters: f=0.6 mL·cm−3·min−1, S=150 cm2.cm−3 brain,
Vaq_P=0.98 solvent/mL plasma and Vaq_T=0.9 solvent/mL tissue. In
addition, a scaling factor of 3.43 was introduced to account for in
vitro–in vivo differences in K1 (Guo et al., 2009).
BPND can be predicted from fND, Bmax and KD for a single target.
Here, we extended the model to account for multiple TSPO binding
classes by considering the different afﬁnities for binding of the radi-
oligands. BPND was predicted depending on the binding class status
(HABs, MABs and LABs) as:
BPND
¼ f ND
BmaxH
KDH
for HABs
¼ f ND
BmaxMH
KDH
þ f ND
BmaxML
KDL
for MABs
¼ f ND
BmaxL
KDL
for LABs
ð4Þ
where KDH and KDL are the high and low afﬁnities for TSPO for each
ligand, BmaxH and BmaxL are the density of TSPO in HABs, LABs, andBmaxMH and BmaxML are the density of high afﬁnity sites and low afﬁn-
ity sites in MABs. Here, Ki values were used instead of KD for all the
compounds considered to be consistent.
Using these parameters, time activity curves (TACs) were generat-
ed for both target and non-displaceable tissue using a standard plas-
ma input function as follows:
CT tð Þ ¼ 1−VBð ÞK1e−
k2
1þBPND
t  CP tð Þ þ VBCB tð Þ ð5Þ
CND tð Þ ¼ 1−VBð ÞK1e−k2t  CP tð Þ þ VBCB tð Þ ð6Þ
where CT(t) and CND(t) are the concentration of the radioligands in
total tissue and non-displaceable compartment respectively; CP(t)
and CB(t) are the concentration in plasma and whole blood respec-
tively, and VB is the blood volume. Here the VB was ﬁxed to 5% in
the estimation, and we used an 11C-(R)-PK11195 human input func-
tion as a standard input for all the radioligands. The validity of using
a standard input function has been veriﬁed in Guo et al. (2009).
Within-subject performance assessment
The within-subject performance of the radioligands was assessed
in terms of the numerical identiﬁability of the speciﬁc signal (BPND)
and the power to monitor disease progression in longitudinal studies.
Here, the BPND was chosen as the primary outcome measure of inter-
est, and the identiﬁability of the BPND was evaluated in terms of its
coefﬁcient of variation (%COV[BPND]), which can be estimated from
Monte Carlo simulations.
In order to estimate the %COV[BPND], the K1, k2 and BPND predicted
from in silico/in vitro data were used in conjunction with the 1TCM to
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quently, 1000 noisy realisations were generated with noise added to
the non-decay corrected data. The variance of the noise was propor-
tional to the non-decay corrected radioactivity/frame duration, and
the scale of noise was determined based on experiences with the
noise level found in actual in vivo ROI based TACs. The simulated
TACs with noise were then decay corrected considering different
isotopes (Logan et al., 2011) and the 1TCM was ﬁtted to both the
non-displaceable and the total tissue data to derive estimates of
BPND as BPND=VT /VND−1, where VT and VND are the volumes of dis-
tribution estimated from K1/k2 in the total and non-displaceable com-
partments respectively. This Monte Carlo simulation then allowed for
the calculation of %COV[BPND]:
%COV BPND½  ¼
σ BPNDð Þ
μ BPNDð Þ
 100% ð7Þ
where σ(BPND) is the standard deviation and μ(BPND) is the mean of
the BPND estimates derived from the simulations. This metric was
used to assess radioligand performance, with a smaller %COV[BPND]
value indicating a better radioligand.
A %COV[BPND] was produced for each binding class with each radi-
oligand. In order to estimate the identiﬁability of the BPND for a dis-
eased population, the Bmax of TSPO for all the binding classes was
increased by 50% and 400% to approximate a moderate and high in-
crease of TSPO, and the simulations were performed to estimate the
%COV[BPND] accordingly. 50% and 400% were chosen to represent dis-
eases with various levels of TSPO increase, i.e. about 50% increase as
found in schizophrenia (Doorduin et al., 2009) and about 400% in
amyotrophic lateral sclerosis (ALS) (Venneti, et al., 2008). Note that
there will be some inter-subject variability for the increase in binding.
However, as the exact levels of TSPO changes are not known precisely
for different diseases, here we ﬁxed the increase level to 50% and
400% as a ﬁrst order approximation to identify whether these 2nd
generation ligands are improvements over 11C-(R)-PK11195.
In addition, to evaluate the capabilities of the radioligands to mon-
itor disease progression, we performed power analyses to estimate
the sample size required with each radioligand to detect 50% or
400% change in the TSPO density within subject. A population of
1000 subjects was simulated for each binding class separately
(HABs, MABs and LABs) using the biomathematical modelling
approach with 10% variation in K1 and k2 and 25% in Bmax to account
for the variability in the population. For each subject, TACs were gen-
erated with Bmax at a normal value as well as at both diseased levels
with ﬁxed values for K1 and k2. BPND was estimated for all the realisa-
tions of these three TACs for each binding class. The mean and the
variance of BPND were then calculated from each group (HABs,
MABs and LABs) in the population, and the sample size required for
90% power was assessed using a paired t-test with α=0.05.
Between-subject performance assessment
The multiple binding classes introduce a higher complexity for
interpreting the differences in binding signals between subjects.
Here, we aim to evaluate the capability of the ligands to distinguish
between groups of diseased and healthy subjects when binding
class status is either known or unknown. For the scenario when the
binding class status is not available, a population of 1000 subjects
containing all binding classes was simulated based on the biomathe-
matical modelling approach. Since there is a difference in the fre-
quencies of the rs6971 polymorphism in different ethnic groups,
namely Caucasians, African Americans, Han Chinese and Japanese,
we evaluated each group separately. The proportion of each binding
class in the Caucasian population used for simulation is HAB:MAB:
LAB=49:42:9, and 56:38:6 for African Americans and 94:6:0.001
for Chinese and Japanese (Owen et al., 2012), and these proportionsare ﬁxed according to the polymorphism frequency in each ethnic
group. The percentage of HABs, MABs and LABs were assumed to
be the same in the control group and in the pathological cohort.
Within each population, the variability for different subjects
was considered by adding 10% variability to K1, 20% to k2, and within
each binding class, 25% to Bmax. Mean and variance of the BPND of the
healthy and diseased groups were estimated from the total
population.
Power analyses were performed to calculate the sample size re-
quired to detect a 50% or 400% difference between the two groups
(0.9 power using two sample t-test with different variances). Note
that when different binding classes are mixed together, the distribu-
tion of the total population is not normal any more. A Mann–Whitney
U test was used for the power calculation for the mixed population
rather than t-test. The sample size required for a U test was estimated
by a correction of the Pitman Asymptotic Relative Efﬁciency (A.R.E.)
to the t-test sample size (Randles and Wolfe, 1979).
In addition, sample sizes were also calculated under the assump-
tion that the binding class information is known a priori. In this
case, subjects can be separated into different binding classes, which
allows for a comparison of healthy and diseased groups within each
binding class. A two sample t-test was used for these analyses.
Results
Estimation of the in silico and in vitro parameters
The in silico/in vitro data required by the biomathematical models
to predict the in vivo parameters are listed in Table 1. In contrast to
11C-(R)-PK11195 which has a very small free fraction in tissue
(fND=0.01), all the 2nd generation radioligands have a much higher
fND, indicating much lower non-speciﬁc binding in tissue. In addition,
the new ligands have higher afﬁnities for HABs than 11C-(R)-PK11195
does, although with signiﬁcantly lower afﬁnities for LABs. 11C-(R)-
PK11195 displayed similar afﬁnity for both HABs and LABs with an af-
ﬁnity ratio indistinguishable from 1 (0.8; Owen et al., 2011). Bmax
values for HABs, MABs, and LABs measured in a homogenate satura-
tion assay using 3H-PBR28 were used for 18F-PBR111 and 11C-
DPA713 as well. The Bmax values for 11C-(R)-PK11195 were measured
separately using a homogenate saturation assay and 3H-PK11195.
Here we assumed that the TSPO density of both the high and low
afﬁnity sites in MABs is the same (Bmax-MH=Bmax-ML=50% Bmax-M;
Owen et al., 2010).
Comparison of the radioligand performance in within-subject studies
The predicted in vivo K1, k2 and BPND values are listed in Table 2.
11C-(R)-PK11195 shows lower brain entry compared to the other
ligands represented by a smaller K1. For both HABs and MABs, the
new ligands have 2 to 20 fold higher BPND values as compared to
11C-(R)-PK11195.
Time activity curves were predicted for each radioligand, for each
binding class, at both normal and diseased states (Fig. 2). In general,
the new radioligands demonstrate a much higher uptake and speciﬁc
to non-speciﬁc binding ratio as compared to 11C-(R)-PK11195 for
HABs and MABs in all conditions. For LABs, at normal and moderate
TSPO levels, the new ligands produced lower speciﬁc binding signal
similar to 11C-(R)-PK11195. This is consistent with the overall predic-
tion results represented by %COV[BPND] (see Table 3). The model pre-
dicted small %COV[BPND] values for all the new ligands (b5%) for both
HABs and MABs at all states whereas the %COV[BPND] of 11C-(R)-
PK11195 is higher than 15% in all scenarios. For LABs, all the other
2nd generation ligands showed a much smaller %COV[BPND] at all
states except 11C-PBR28 which had a signiﬁcantly lower afﬁnity for
low afﬁnity binding sites. However, when there are high levels of
Table 1
In silico and in vitro properties of radioligands.
Radioligands In silico In vitro equilibrium dialysis In vitro homogenate binding
Vx clogD fp fND Bmax-H Bmax-M
a Bmax-L Ki-H Ki-L
18F-PBR111 3.10 4.0 0.19±0.018
(n=6)
0.06±0.005
(n=6)
193±66
(n=6)
186±37
(n=4)
99.4±35
(n=5)
15.6±3.7
(n=5)
61.8±10.7
(n=5)
11C-PBR28 2.69 2.8 0.16±0.044
(n=6)
0.07±0.006
(n=6)
193±66
(n=6)
186±37
(n=4)
99.4±35
(n=5)
3.40±0.2
(n=6)
188±7.0
(n=5)
11C-DPA713 2.91 3.0 0.33±0.034
(n=6)
0.12±0.006
(n=6)
193±66
(n=6)
186±37
(n=4)
99.4±35
(n=5)
15.0±2.2
(n=5)
66.4±7.8
(n=4)
11C-(R)-PK11195 2.74 4.9 0.14±0.039
(n=4)
0.01±0.002
(n=6)
433±154
(n=9)
433±154b
(n=9)
506±131
(n=5)
28.3±4.0
(n=6)
22.3±2.2
(n=5)
Units for Vx is cm3 mol−1/100; units for Bmax and Ki are nM; clogD, fP and fND are unitless. Bmax and Ki values were obtained from Owen et al. (2010, 2011).
a Bmax_M is for both high and low afﬁnity binding sites for MABs, and Bmax-MH and Bmax_ML values are 50% of the total Bmax_M as suggested by the two-site model in Owen et al.
(2010).
b Bmax_H was used as Bmax_M for 11C-(R)-PK11195 as there is no signiﬁcant difference between Bmax_H and Bmax_L for this ligand as shown in Owen et al. (2010).
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which was much smaller than 11C-(R)-PK11195 (17%).
The sample sizes required for longitudinal studies within subjects
using these ligands were consistent with their %COV[BPND] estimates
(Table 4). For HABs and MABs, it required 3 to 4 subjects in the con-
trol and diseased groups to identify a 50% change in TSPO density
(90% power) except 11C-PBR28 for LABs, whilst 11C-(R)-PK11195
requires over 15 subjects in each group. To identify a 400% increase,
the sample size required for all ligands was similar with around 3 to
4 subjects required in each group.
Comparison of the radioligand performance in between-subject studies
When no information is available on binding class a priori, even
when all of the subjects are healthy, the variance of the BPND values
can be very large depending on which radioligand is used and its
high:low binding site afﬁnity ratio.
We simulated the binding of a population of 1000 healthy controls
from different binding classes, and an example of BPND histograms of
Caucasians is shown in Fig. 3. Also we ﬁtted the histogram of each in-
dividual binding class in the population separately. The plot shows
that for 18F-PBR111, 11C-PBR28 and 11C-DPA713, the distribution of
the BPND appears to be tri-normal rather than the normal behaviour
observed for 11C-(R)-PK11195. This is due to the large afﬁnity ratios
for the three new ligands (~4 for 18F-PBR111, ~55 for 11C-PBR28
and ~4 for 11C-DPA713 compared to 11C-(R)-PK11195, which has an
afﬁnity ratio of approximately 1) and is consistent with the three
binding classes.
The multiple afﬁnities of these new ligands for different subjects
lead to a large variance of the binding potential within a population,
which would further require more samples to detect a difference
between the healthy controls and the diseased subjects. However,
the sample size required for between-subject studies is also related
to the reproducibility of the ligand itself, in other words, the within-
subject variability of the radioligand.
The sample sizes required to detect 50% and 400% increase of TSPO
in studies comparing different populations when the binding class isTable 2
In vivo prediction of K1, k2 and BPND for each radioligand and binding class in normal
subjects.
Radioligands K1 k2 BPND
HAB MAB LAB
18F-PBR111 0.25 0.08 0.72 0.44 0.09
11C-PBR28 0.53 0.25 3.99 1.96 0.04
11C-DPA713 0.48 0.19 1.60 0.94 0.19
11C-(R)-PK11195 0.09 0.01 0.20 0.23 0.30
Units for K1 and k2 are mL·cm−3·min and min−1 respectively; BPND is unitless.unknown for all the ethnic groups considered here are listed in
Table 5. It shows that the sample sizes required by the 2nd generation
ligands to characterise a 50% change in TSPO are higher (33 to 49) com-
pared to 11C-(R)-PK11195 (~29) in Caucasians. Fewer samples (~4 to 8)
are needed to characterise a 400% change with all radioligands. In
African Americans, similar performances of all ligands were predicted
(sample size ~29) except 11C-PBR28, which requires more samples to
detect 50% increase in TSPO density. In Han Chinese and Japanese, the
2nd generation ligands signiﬁcantly outperformed 11C-(R)-PK11195
by reducing sample size to detect 50% density difference by half.
We also estimated the sample size required if the binding class in-
formation was known a priori (Table 6). In this case, subjects in the
control group and the diseased group were divided into different
binding classes and compared within their own class. The sample
sizes required for the new ligands to detect 50% change reduced to
about 10 subjects except 11C-PBR28 for LABs (which requires 22 sub-
jects), whilst 11C-(R)-PK11195 still requires more than 20 subjects.
Discussion
In this study, the in vivo performance of three 2nd generation
TSPO ligands (namely 18F-PBR111, 11C-PBR28, and 11C-DPA713)
and 11C-(R)-PK11195 was predicted directly from in silico/in vitro
data using a biomathematical modelling approach (Guo et al., 2009)
which has been extended here to account for tracers with multiple
binding sites. These radioligands were chosen because the in vitro
data required by the models had been acquired previously. The radi-
oligands were compared in terms of their performances in within-
subject studies and between-subject studies based on this modelling
approach. The models predict that the 2nd generation TSPO radioli-
gands are better ligands than 11C-(R)-PK11195 for both longitudinal
and disease characterisation studies that take into account the bind-
ing status.
This process of predicting in vivo behaviour from in silico and in
vitro data is complex and rests on a number of modelling assump-
tions which are important to consider. The method uses a 1TC
model to characterise the tissue kinetics of the radioligands under
the assumption that the radioligand equilibrates rapidly between all
tissue compartments. Though this may not always be the case and
in practice, the in vivo data may be analysed by other quantiﬁcation
methods rather than 1TC, given the overall complexity of in vivo pre-
diction directly from in silico and in vitro data, the assumption was
reasonable and allowed for a parsimonious description. It has been
shown previously that a wide range of tracers and binding levels
can be successfully approximated by a 1TC in the context of predict-
ing the performance of radioligands via the %COV of BPND (Guo
et al., 2009). The relative power of the tracers will to a large extent
hold true regardless of the quantiﬁcation method used, as the main
driven factors are the characteristics of the chemical compounds.
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Fig. 2. Prediction of the TACs for each radioligand for all the binding classes in both normal and diseased states with moderate (50% increase) and high (400% increase) levels of
TSPO. T: total tissue; ND: nondisplaceable tissue.
Table 4
Sample size required for within-subject longitudinal studies.
Binding
class
50% increase 400% increase
Mean
ΔBPND
SD
ΔBPND
Sample
size
Mean
ΔBPND
SD
ΔBPND
Sample
size
18F-PBR111
HAB 0.357 0.094 3 2.874 0.726 3
MAB 0.219 0.054 3 1.748 0.428 3
LAB 0.047 0.016 4 0.378 0.096 3
907Q. Guo et al. / NeuroImage 60 (2012) 902–910Here, a plasma input function obtained from a previous human 11C-
(R)-PK11195 study was used as a standard input function for all the
radioligands and TACs of 90 min duration were simulated. Although
the pharmacokinetics of the ligands might be different and longer
scanning time might be optimal for some of the ligands such as 18F-
PBR111, we had found previously that small variations in the input
function do not have a signiﬁcant impact on the overall prediction
and this is a consequence of the outcome measure of interest, BPND,
being a ratio of two distribution volumes (VT and VND) which rely
on the same input (Guo et al., 2009). The estimates of the plasma
and tissue free fractions were measured in pig tissue using equilibri-
um dialysis. fND has been shown to be consistent across species
(Summerﬁeld et al., 2008) although there could be species differences
in fP. Larger fp values measured in human blood using ultraﬁltration
have been shown in Fujita et al. (2008) and Endres et al. (2009).
More understanding is required around differences between ultraﬁl-
tration and dialysis measurements particularly at low concentrations.Table 3
%COV[BPND] for all the ligands in normal and diseased states.
Radioligands Controls Disease I
(50% increase)
Disease II
(400% increase)
HAB MAB LAB HAB MAB LAB HAB MAB LAB
18F-PBR111 1.47 2.10 7.71 1.19 1.64 5.48 0.91 0.93 1.95
11C-PBR28 1.30 1.55 33.1 1.26 1.31 22.43 1.71 1.27 7.57
11C-DPA713 1.61 2.16 6.98 1.45 1.75 4.95 1.29 1.26 2.12
11C-(R)-
PK11195
36.2 32.2 27.3 27.2 25.8 22.7 17.00 16.5 17.0In addition, the measurement of other parameters in vitro, such as the
afﬁnity of the radioligands for TSPO, may differ from the actual values
in vivo due to assay conditions or differences in the tissue environ-
ment in vivo.
However, in general, the models generated reasonable predictions
for the radioligands. In the literature, the in vivo BPND value for 11C-11C-PBR28
HAB 1.997 0.503 3 15.88 3.945 3
MAB 0.983 0.239 3 7.759 2.043 3
LAB 0.018 0.023 19 1.496 0.379 3
11C-DPA713
HAB 0.769 0.194 3 6.187 1.517 3
MAB 0.460 0.118 3 3.650 0.904 3
LAB 0.091 0.032 4 0.721 0.184 3
11C-(R)-PK11195
HAB 0.071 0.109 27 0.619 0.236 4
MAB 0.091 0.115 19 0.701 0.260 4
LAB 0.113 0.129 16 0.934 0.342 4
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Fig. 3. Predicted BPND distributions for 18F-PBR111, 11C-PBR28, 11C-DPA713 and 11C-(R)-PK11195 from a population of 1000 healthy Caucasians consisting of HABs, MABs and LABs.
908 Q. Guo et al. / NeuroImage 60 (2012) 902–910(R)-PK11195 in healthy brain is around 0.23–0.45 (Turkheimer et al.,
2007), and the model prediction is around 0.2. The in vivo K1 values in
the literature for 11C-PBR28 (0.10–0.14 mL/cm3/min) and 11C-
DPA713 (0.20–0.29 mL/cm3/min) are higher than 11C-(R)-PK11195
(0.016–0.026 mL/cm3/min) (Endres et al., 2009; Fujita et al., 2008).
This is consistent with our prediction which indicated that the 2nd
generation TSPO ligands considered here enter the brain well with
K1 values higher (0.25–0.48 mL/cm3/min) than that of 11C-(R)-
PK11195 (0.09 mL/cm3/min). In addition, as fND is an index of non-
speciﬁc binding, the much higher values for the 2nd generation li-
gands are consistent with them having lower non-speciﬁc binding
as compared to 11C-(R)-PK11195.
Overall, the models predicted that the new radioligands perform
better in vivo than 11C-(R)-PK11195 for HABs and MABs in both nor-
mal and diseased states as represented by smaller %COV[BPND] values.
For longitudinal studies, the models predicted that the new ligands
have better numerical identiﬁability than 11C-(R)-PK11195, and as a
result, fewer subjects would be required to detect moderate TSPO in-
crease. When considering variability between subjects in addition to
the variability within subject, because of the different afﬁnities ofTable 5
Sample size required for between-subjects studies when binding class information is unkn
Radioligand 50% increase
Mean BPND_disease−Mean
BPND_control
SD
BPND_control
SD
BPND_disease
S
s
Caucasians
18F-PBR111 0.270 0.242 0.362 3
11C-PBR28 1.396 1.506 2.290 4
11C-DPA713 0.592 0.543 0.817 3
11C-(R)-PK11195 0.109 0.101 0.129 2
African Americans
18F-PBR111 0.286 0.234 0.350 2
11C-PBR28 1.502 1.460 2.228 4
11C-DPA713 0.625 0.525 0.793 2
11C-(R)-PK11195 0.107 0.099 0.126 2
Han Chinese and Japanese
18F-PBR111 0.353 0.187 0.274 1
11C-PBR28 1.955 1.082 1.666 1
11C-DPA713 0.771 0.418 0.637 1
11C-(R)-PK11195 0.097 0.092 0.117 3the radioligands for different binding sites, the distribution of a
mixed population of subjects from all the binding groups is not nor-
mal any more. We simulated the possible distribution of the binding
potentials within a population and it demonstrated the same pattern
as the distribution of the VT values observed in vivo in a previous
study using 11C-PBR28 (Owen et al., 2011). For between-subject stud-
ies when subjects from different binding classes are considered to-
gether, power analyses were performed to estimate the sample
sizes required for the ligands to distinguish diseased from healthy
subjects. The models predicted that the effect size for 11C-(R)-
PK11195 to identify a 50% difference in TSPO level is about 1, which
is consistent with in vivo ﬁndings such as in Tomasi et al. (2008),
where 11C-(R)-PK11195 was used to characterise Alzheimer's
disease.
Note that due to the different rs6971 polymorphism frequencies
in the ethnic groups considered here in between-subject studies,
when the binding class information is not known, the performance
of the 2nd generation ligands is signiﬁcantly better than 11C-(R)-
PK11195 in Chinese and Japanese, similar in African Americans and
slightly less competent in Caucasians. This indicates that caution isown.
400% increase
ample
ize
Mean BPND_disease−Mean
BPND_control
SD
BPND_control
SD
BPND_disease
Sample
size
3 2.187 0.249 1.225 7
9 11.14 1.507 7.608 8
5 4.804 0.551 2.732 7
9 0.887 0.101 0.384 6
8 2.305 0.242 1.181 4
0 11.97 1.460 7.396 7
9 5.080 0.533 2.646 6
9 0.870 0.099 0.371 6
3 2.813 0.194 0.949 5
4 15.50 1.073 5.609 5
3 6.244 0.425 2.104 5
0 0.815 0.090 0.328 5
Table 6
Sample size required for between subject studies when binding class information is known a priori.
Binding
class
50% increase 400% increase
Mean BPND_disease−Mean
BPND_control
SD
BPND_control
SD
BPND_disease
Sample size
t-test
Mean BPND_disease−Mean
BPND_control
SD
BPND_control
SD
BPND_disease
Sample size
t-test
18F-PBR111
HAB 0.349 0.182 0.265 10 2.879 0.184 0.906 4
MAB 0.214 0.111 0.164 10 1.762 0.117 0.559 4
LAB 0.044 0.028 0.040 14 0.370 0.025 0.118 4
11C-PBR28
HAB 2.021 0.992 1.531 10 15.99 0.979 5.182 4
MAB 0.956 0.498 0.753 11 7.880 0.499 2.501 4
LAB 0.019 0.017 0.021 22 0.149 0.018 0.049 4
11C-(R)-DPA713
HAB 0.790 0.397 0.606 10 6.399 0.403 1.999 4
MAB 0.464 0.243 0.358 10 3.813 0.239 1.150 4
LAB 0.093 0.051 0.072 11 0.725 0.048 0.238 4
11C-(R)-PK11195
HAB 0.095 0.092 0.116 27 0.810 0.088 0.324 4
MAB 0.119 0.100 0.122 20 0.903 0.100 0.360 4
LAB 0.140 0.117 0.155 21 1.220 0.112 0.474 4
909Q. Guo et al. / NeuroImage 60 (2012) 902–910needed when the 2nd generation ligands are used in Caucasians
because of the existence of relatively large proportion of LABs.
However, if we know the binding class information of subjects a
priori, and are able to stratify subjects and compare them within
the same binding class, the 2nd generation ligands require much
fewer samples to detect a moderate TSPO increase. Fig. 4 shows sim-
ulations of 10 random samples from a population of either the full
population or HABs only at normal and 50% TSPO increase states.
This ﬁgure demonstrates the superiority of the 2nd generation li-
gands when there is a priori knowledge of the binding class of each
subject. When only HABs are included for example, there is clearer
separation between the control and diseased groups with higher
BPND compared to 11C-(R)-PK11195.
Recent work conducted by Owen and colleagues nowmakes iden-
tiﬁcation of the binding class of individuals feasible from either a ge-
netic test or a peripheral blood assay. This allows TSPO binding class
to be determined by a simple genetic test prior to quantitative PET
scans of TSPO expression, and gives increased value and conﬁdence
in using the 2nd generation TSPO radioligands.Control Diseased
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Fig. 4. Simulations of 10 random samples from a population of mixed subjects and HABs on
different binding classes; bottom row: HABs only.In general, the predicted performances of all the 2nd generation
tracers examined were roughly similar with each other, with 11C-
DPA713 and 18F-PBR111showing higher numerical identiﬁability
within all binding classes whilst 11C-PBR28 was not very promising
for LABs. However, these differences were modest and below the
level of conﬁdence provided by the biomathematical modelling ap-
proach, In vivo human PET studies will help clarify a frontrunner
amongst the 2nd generation TSPO PET probes.
Conclusions
The biomathematical modelling approach is a useful tool to pre-
dict and compare the in vivo performance of TSPO radioligands di-
rectly from in silico/in vitro data prior to intensive radiochemistry
and preclinical/clinical experimentation. The approach considers
brain entry, speciﬁc/non-speciﬁc binding and kinetics as well as mul-
tiple afﬁnity binding to two sites. The models predict that the
2nd generation TSPO radioligands considered here, namely 18F-
PBR111, 11C-PBR28 and 11C-DPA713, are better than 11C-(R)-PK11195BP
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ly at normal and moderate TSPO increase states (50%). Top row: mixed subjects from
910 Q. Guo et al. / NeuroImage 60 (2012) 902–910for both longitudinal and disease characterisation studies if binding
class information is known a priori. Combined with recent work that
allows binding class to be identiﬁed from a single polymorphism
(rs6971) in the TSPO gene or a platelet assay, this demonstrates the
great potential of using 2nd generation TSPO radioligands for PET stud-
ies of neuroinﬂammation.
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